PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have represented an important change in the management of hypercholesterolemia, although, until now, they have barely been used. Without PCSK9i, many patients with atherosclerotic cardiovascular disease (CVD) or those at v...

Descripción completa

Detalles Bibliográficos
Autores: Marco-Benedí V, Sánchez-Hernández RM, Díaz JL, Jarauta E, Suárez-Tembra M, Pintó X, Morillas C, Plana N, Pedro-Botet J, Civeira F
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p17692
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/17692
Access Level:acceso abierto
Palabra clave:Familial hypercholesterolemia
LDL-cholesterol
PCSK9 inhibitors
Primary prevention
Secondary prevention
id ES_08887bdfd1dbf299070d9a50adcd71e7
oai_identifier_str oai:fisabio.fundanetsuite.com:p17692
network_acronym_str ES
network_name_str España
repository_id_str
spelling PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.Marco-Benedí VSánchez-Hernández RMDíaz JLJarauta ESuárez-Tembra MPintó XMorillas CPlana NPedro-Botet JCiveira FFamilial hypercholesterolemiaLDL-cholesterolPCSK9 inhibitorsPrimary preventionSecondary preventionBACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have represented an important change in the management of hypercholesterolemia, although, until now, they have barely been used. Without PCSK9i, many patients with atherosclerotic cardiovascular disease (CVD) or those at very high risk do not reach their therapeutic LDLc objectives. OBJECTIVE: The analysis aimed to examine the clinical and biochemical characteristics of subjects receiving PCSK9i treatment in the Dyslipidemia Registry of the Spanish Atherosclerosis Society. METHODS: All consecutive subjects aged = 18 years from different Lipid Units included in the Dyslipidemia Registry of the SEA were analyzed. Inclusion criteria consisted of unrelated patients aged = 18 at the time of inclusion with hypercholesterolemia (LDL-C = 130 mg/dL or non-HDL-C = 160 mg/dL after the exclusion of secondary causes) who were studied for at least two years after inclusion. Participants' baseline and final visit clinical and biochemical characteristics were analyzed based on whether they were on primary or secondary prevention and whether they were taking PCSK9i at the end of follow-up. RESULTS: Eight hundred twenty-nine patients were analyzed, 7014 patients in primary prevention and 1281 in secondary prevention at baseline. 4127 subjects completed the required follow-up for the final analysis. The median follow-up duration was 7 years (IQR 3.0-10.0). Five hundred patients (12.1%) were taking PCSK9i at the end of the follow-up. The percentage of PCSK9i use reached 35.6% (n = 201) and 8.7% (n = 318) in subjects with and without CVD, respectively. Subjects on PCSK9i and oral lipid-lowering agents with and without CVD achieved LDLc reductions of 80.3% and 75.1%, respectively, concerning concentrations without lipid-lowering drugs. Factors associated with PCSK9i use included increasing age, LDLc without lipid-lowering drugs and the Dutch Lipid Clinic Network (DLCN) score. However, hypertension, diabetes, smoking, and LDLc after oral lipid-lowering drugs were not independent factors associated with PCSK9i prescription. In subjects with CVD, the use of PCSK9i was higher in men than in women (an odds ratio of 1.613, P = 0.048). CONCLUSIONS: Approximately one-third of CVD patients received PCSK9i at the end of follow-up. The use of PCSK9i was more focused on baseline LDLc concentrations rather than on CVD risk. Women received less PCSK9i in secondary prevention compared to men.BMC2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/17692Lipids in Health and DiseaseISSN: 1476511Xreponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p176922026-06-11T12:45:17Z
dc.title.none.fl_str_mv PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
title PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
spellingShingle PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
Marco-Benedí V
Familial hypercholesterolemia
LDL-cholesterol
PCSK9 inhibitors
Primary prevention
Secondary prevention
title_short PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
title_full PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
title_fullStr PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
title_full_unstemmed PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
title_sort PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
dc.creator.none.fl_str_mv Marco-Benedí V
Sánchez-Hernández RM
Díaz JL
Jarauta E
Suárez-Tembra M
Pintó X
Morillas C
Plana N
Pedro-Botet J
Civeira F
author Marco-Benedí V
author_facet Marco-Benedí V
Sánchez-Hernández RM
Díaz JL
Jarauta E
Suárez-Tembra M
Pintó X
Morillas C
Plana N
Pedro-Botet J
Civeira F
author_role author
author2 Sánchez-Hernández RM
Díaz JL
Jarauta E
Suárez-Tembra M
Pintó X
Morillas C
Plana N
Pedro-Botet J
Civeira F
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Familial hypercholesterolemia
LDL-cholesterol
PCSK9 inhibitors
Primary prevention
Secondary prevention
topic Familial hypercholesterolemia
LDL-cholesterol
PCSK9 inhibitors
Primary prevention
Secondary prevention
description BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have represented an important change in the management of hypercholesterolemia, although, until now, they have barely been used. Without PCSK9i, many patients with atherosclerotic cardiovascular disease (CVD) or those at very high risk do not reach their therapeutic LDLc objectives. OBJECTIVE: The analysis aimed to examine the clinical and biochemical characteristics of subjects receiving PCSK9i treatment in the Dyslipidemia Registry of the Spanish Atherosclerosis Society. METHODS: All consecutive subjects aged = 18 years from different Lipid Units included in the Dyslipidemia Registry of the SEA were analyzed. Inclusion criteria consisted of unrelated patients aged = 18 at the time of inclusion with hypercholesterolemia (LDL-C = 130 mg/dL or non-HDL-C = 160 mg/dL after the exclusion of secondary causes) who were studied for at least two years after inclusion. Participants' baseline and final visit clinical and biochemical characteristics were analyzed based on whether they were on primary or secondary prevention and whether they were taking PCSK9i at the end of follow-up. RESULTS: Eight hundred twenty-nine patients were analyzed, 7014 patients in primary prevention and 1281 in secondary prevention at baseline. 4127 subjects completed the required follow-up for the final analysis. The median follow-up duration was 7 years (IQR 3.0-10.0). Five hundred patients (12.1%) were taking PCSK9i at the end of the follow-up. The percentage of PCSK9i use reached 35.6% (n = 201) and 8.7% (n = 318) in subjects with and without CVD, respectively. Subjects on PCSK9i and oral lipid-lowering agents with and without CVD achieved LDLc reductions of 80.3% and 75.1%, respectively, concerning concentrations without lipid-lowering drugs. Factors associated with PCSK9i use included increasing age, LDLc without lipid-lowering drugs and the Dutch Lipid Clinic Network (DLCN) score. However, hypertension, diabetes, smoking, and LDLc after oral lipid-lowering drugs were not independent factors associated with PCSK9i prescription. In subjects with CVD, the use of PCSK9i was higher in men than in women (an odds ratio of 1.613, P = 0.048). CONCLUSIONS: Approximately one-third of CVD patients received PCSK9i at the end of follow-up. The use of PCSK9i was more focused on baseline LDLc concentrations rather than on CVD risk. Women received less PCSK9i in secondary prevention compared to men.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/17692
url https://fisabio.portalinvestigacion.com/publicaciones/17692
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv Lipids in Health and Disease
ISSN: 1476511X
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403048397242368
score 15,81155

Similares en LA Referencia